The aim of this study is to assess the feasibility of identifying people who are resident in care homes (nursing homes and residential care homes) using the CPRD. We also aim to assess how well data is captured in CPRD during care home residency. Care home residents may have different risks of events than the non-care home populations and they may receive different standards of care than non-care home residents. If considered feasible, we plan to conduct a future study to assess osteoporosis outcomes and treatments in the care home population.
Being able to identify people who are resident in care home using the CPRD may have research utility across multiple diseases and treatments. A recently-published study defined a set of Read and medical codes, which indicated a high level of completeness for recording residency information in CPRD, comparable with English census data [Jain et al. PLoS One. 2017;12:e0189038]. The codes provided in this publication will be used in the current feasibility study.
Objectives:
1. Evaluate the count of patients who get newly-admitted to a nursing or residential care home.
2. Describe the recording of residency information for patients who are newly-admitted to a nursing or residential care home.
3. Describe the demographics and characteristics of patients at the time of admission to a nursing or residential care home
4. Describe patterns of care before and after admission to a nursing or residential care home.
Residency will be categorized as either nursing/residential care home or non-nursing/residential care home. Although there is a difference between nursing homes and residential care homes, many of the Read terms do not distinguish between them or are ambiguous. Therefore, we will group them together for the purposes of the study.
HES data will be used to increase the completeness of residency information as previously reported in Jain et al. ONS Death Registration Data will be used to confirm death events.
Number of patients with at least one record of residency within a care home during the study period; number of patients with a record of residency within care home after the index date; number of patients with a record of residency outside a care home after the index date; duration of follow up and reasons for end of follow up; number of GP visits after the index date that record place of residency; frequency of diagnoses with osteoporosis, diabetes, rheumatoid arthritis, urinary tract infection, and cellulitis before and after care home admission; frequency of prescriptions for medications for osteoporosis, diabetes, rheumatoid arthritis, and urinary tract infection before and after care home admission.
James O'Kelly - Chief Investigator - Amgen Ltd
James O'Kelly - Corresponding Applicant - Amgen Ltd
Joe Maskell - Collaborator - Amgen Ltd
Victoria Banks - Collaborator - Amgen Ltd
HES Admitted Patient Care;ONS Death Registration Data